Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rapport Therapeutics, Inc. (RAPP)
:RAPP
RAPP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.09 - $29.74
Previous CloseN/A
Volume10.11K
Average Volume (3M)101.49K
Market Cap
$475.49M
Enterprise Value$429.97M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.42
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,576,458
10 Day Avg. Volume98,041
30 Day Avg. Volume101,492
Standard Deviation0.12
R-Squared0.00043
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.84K
Enterprise Value/Ebitda-5.93
Forecast
1Y Price Target
$37.33Price Target Upside187.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Rapport Therapeutics, Inc. News
PremiumCompany Announcements
Rapport Therapeutics’ Promising Trial Results and Leadership Change
PremiumCompany Announcements
Rapport Therapeutics Reports Q3 Financials and Strategic Updates---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe positron emission tomography (PET) trial demonstrated high target receptor occupancy and TARPγ8 localization in key areas of CNS associated with refractory focal epilepsy.
Product DevelopmentRAPP continues working on the development of a long-acting injectable formulation of RAP-219 as the first potential anti-seizure medication in a depot formulation.
Bears Say
Regulatory ChallengesIND application for Phase IIa trial of RAP-219 in diabetic peripheral neuropathic pain placed on clinical hold by the FDA.
---
Ownership Overview
Currently, No data available
---
RAPP FAQ
What was Rapport Therapeutics, Inc.’s price range in the past 12 months?
Rapport Therapeutics, Inc. lowest stock price was $12.09 and its highest was $29.74 in the past 12 months.
What is Rapport Therapeutics, Inc.’s market cap?
Rapport Therapeutics, Inc.’s market cap is $475.49M.
When is Rapport Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rapport Therapeutics, Inc.’s earnings last quarter?
Rapport Therapeutics, Inc. released its earnings results on Aug 08, 2024. The company reported -$1.7 earnings per share for the quarter, missing the consensus estimate of -$0.6 by -$1.1.
Is Rapport Therapeutics, Inc. overvalued?
According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued.
Does Rapport Therapeutics, Inc. pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
What is Rapport Therapeutics, Inc.’s EPS estimate?
Rapport Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. has 36,576,458 shares outstanding.
What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?
Rapport Therapeutics, Inc. reported an EPS of -$1.7 in its last earnings report, missing expectations of -$0.6. Following the earnings report the stock price went up 2.868%.
Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RAPP
---
Rapport Therapeutics, Inc. Stock Smart Score
Company Description
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
---
RAPP Stock 12 Month Forecast
Average Price Target
$37.33
▲(187.15% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Neurocrine
―
PTC Therapeutics
―
SAGE Therapeutics
―
Biohaven Ltd.
―
Best Analysts Covering RAPP
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-33.77%
reiterated a buy rating 13 days ago
Copying Paul Matteis's trades and holding each position for 1 Year would result in - of your transactions generating a profit, with an average return of -33.77% per trade.
---